Get the Stockscreener App
10.45
0.48%
-0.05
Elicio Therapeutics Inc stock is traded at $10.45, with a volume of 50,834.
It is down -0.48% in the last 24 hours and up +3.67% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$10.50
Open:
$10.53
24h Volume:
50,834
Relative Volume:
0.58
Market Cap:
$170.57M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.4084
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
-0.67%
1M Performance:
+3.67%
6M Performance:
+109.84%
1Y Performance:
+132.74%
1-Day Range:
$10.40
$10.73
1-Week Range:
$10.37
$11.19
52-Week Range:
$4.05
$12.62
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
10.44 | 171.55M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.29 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.86 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.10 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.20 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
315.81 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Smart tools for monitoring Elicio Therapeutics Inc.’s price action2025 Trade Ideas & Stock Portfolio Risk Management - newser.com
Using data models to predict Elicio Therapeutics Inc. stock movementDip Buying & Intraday High Probability Setup Alerts - newser.com
How Elicio Therapeutics Inc. (9HA) stock reacts to fiscal policiesAnalyst Upgrade & Breakout Confirmation Alerts - newser.com
How Elicio Therapeutics Inc. stock compares to market leadersMarket Volume Summary & Stepwise Entry/Exit Trade Alerts - newser.com
What momentum shifts mean for Elicio Therapeutics Inc.2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Can Elicio Therapeutics Inc. hit a new high this monthMarket Performance Report & Capital Protection Trading Alerts - newser.com
Price action breakdown for Elicio Therapeutics Inc.July 2025 Sector Moves & Daily Entry Point Trade Alerts - newser.com
Using AI based signals to follow Elicio Therapeutics Inc.CPI Data & Capital Protection Trade Alerts - newser.com
How Elicio Therapeutics Inc. (9HA) stock compares with market leaders2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
What makes Elicio Therapeutics Inc. (9HA) stock appealing to growth investors2025 Support & Resistance & Daily Profit Maximizing Trade Tips - newser.com
What machine learning models say about Elicio Therapeutics Inc.2025 EndofYear Setup & Precise Swing Trade Alerts - newser.com
Volatility clustering patterns for Elicio Therapeutics Inc.2025 Historical Comparison & Real-Time Stock Movement Alerts - newser.com
Is Elicio Therapeutics Inc. stock oversold or undervaluedShort Setup & Capital Efficient Trade Techniques - newser.com
Is this a good reentry point in Elicio Therapeutics Inc.2025 Price Action Summary & Free Technical Pattern Based Buy Signals - newser.com
Using R and stats models for Elicio Therapeutics Inc. forecastingJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Ranking Elicio Therapeutics Inc. among high performing stocks via toolsTrade Risk Report & Daily Price Action Insights - newser.com
Elicio Therapeutics Inc. stock chart pattern explainedWeekly Gains Report & Entry Point Strategy Guides - newser.com
Real time alert setup for Elicio Therapeutics Inc. performanceWeekly Investment Recap & Free AI Powered Buy and Sell Recommendations - newser.com
What high frequency data says about Elicio Therapeutics Inc.2025 Analyst Calls & Technical Pattern Alert System - newser.com
Is Elicio Therapeutics Inc. (9HA) stock attractive for growth fundsCEO Change & Low Risk High Win Rate Stock Picks - newser.com
What margin trends mean for Elicio Therapeutics Inc. stockJuly 2025 Snapshot & Daily Entry Point Alerts - newser.com
Identifying reversal signals in Elicio Therapeutics Inc.Weekly Investment Summary & Free Real-Time Volume Trigger Notifications - newser.com
Detecting price anomalies in Elicio Therapeutics Inc. with AIPortfolio Update Report & Verified Technical Trade Signals - newser.com
Why Elicio Therapeutics Inc. (9HA) stock stays undervaluedTrade Analysis Report & Verified Entry Point Signals - newser.com
Is Elicio Therapeutics Inc. (9HA) stock a contrarian opportunityQuarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Applying Elliott Wave Theory to Elicio Therapeutics Inc.July 2025 Pullbacks & Safe Capital Growth Stock Tips - newser.com
Top chart patterns to watch in Elicio Therapeutics Inc.Quarterly Earnings Summary & Daily Technical Forecast Reports - newser.com
How to use a screener to detect Elicio Therapeutics Inc. breakoutsMarket Activity Recap & Risk Managed Trade Strategies - newser.com
Is Elicio Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Fed Impact & Daily Stock Trend Reports - newser.com
How sentiment analysis helps forecast Elicio Therapeutics Inc.Quarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
What technical models suggest about Elicio Therapeutics Inc.’s comebackMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
How moving averages guide Elicio Therapeutics Inc. tradingJuly 2025 WrapUp & Long-Term Safe Return Strategies - newser.com
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.56%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):